Sven Vermeulen
Investment Associate
Get their honest, personalized take on your startup.
Sign in to pitch Sven →At a glance
- Full Name
- Sven Vermeulen
- Title
- Investment Manager, BNP Paribas Fortis Private Equity (also a director of BNP Paribas Fortis Private Equity Management NV / Investment Manager of BNP Paribas Fortis Private Equity Belgium NV)
- Firm
- BNP Paribas Fortis Private Equity
- Firm Type
- Bank-affiliated / corporate private equity (Direct Investments team). *Note: the stub's "Angel Investors" classification does not match the verified evidence — Vermeulen is a professional PE investor, not a seed-stage angel.*
- Investment Stage
- Growth capital, replacement capital, and leveraged buy-out/buy-in — i.e. scale-up and mature companies, not seed. *(The stub's "Seed Round" is not supported by any source.)*
- Check Size
- Firm ticket of roughly €1m–€50m, with a sweet spot of €3m–€25m per transaction
- Target Company Profile
- Established, profitable Belgian scale-ups and mature companies seeking growth, replacement, or buy-out capital; BNP Paribas Fortis PE always takes a minority stake and lets management remain in charge
- Sector Focus
- Generalist — recent firm deals span healthcare/clinical research, biotech, industrial machinery & equipment, medical-waste treatment, agritech/PV and technology & engineering
- Geographic Focus
- Belgium (companies with a strong Belgian anchor)
- Location
- Antwerp / Brussels, Belgium
Background
Sven Vermeulen is an Investment Manager at BNP Paribas Fortis Private Equity, the direct-investment and fund arm of BNP Paribas Fortis, Belgium's largest bank. He holds a Master's degree as a Business Engineer (handelsingenieur) from the University of Antwerp (2004–2009), and is based in the Antwerp/Brussels area. Before his current role he gained markets and finance experience earlier in his career (including exposure to structured/financial products) before moving into principal investing at BNP Paribas Fortis.
Within the firm he sits on the Direct Investments team and holds formal director/manager roles across the group's investment vehicles, including BNP Paribas Fortis Private Equity Management NV and BNP Paribas Fortis Private Equity Belgium NV. BNP Paribas Fortis Private Equity has backed Belgian companies for more than 40 years and is not structured as a closed-end fund, which lets it hold positions for the long term (a typical 5–7 year horizon, often longer) and reinvest in later rounds.
Publicly, Vermeulen is most visible as the deal lead/spokesperson on BNP Paribas Fortis Private Equity's December 2024 minority investment in Anima Research, a leading European clinical-trials center, where he was quoted articulating the firm's ESG-driven investment rationale. His day-to-day work centers on sourcing, executing, and stewarding minority growth and buy-out investments in Belgian scale-ups rather than early-stage angel checks.
Investment Thesis & Focus
- Invests through BNP Paribas Fortis Private Equity's Direct Investments platform, always as a minority shareholder, acting as a "sounding board" that guides strategy while leaving management in control.
- Stage: growth capital, replacement capital, and leveraged buy-out/buy-in (LBO/MBI) — mature, profitable scale-ups, not seed or pre-seed.
- Ticket size: ~€1m–€50m, sweet spot €3m–€25m; can also provide quasi-equity/mezzanine financing.
- Geography/target: Belgian companies (or companies with a strong Belgian footprint) that "drive innovation and growth."
- Horizon: typically 5–7 years but flexible — the evergreen, non-closed-end structure allows longer holds and follow-on reinvestment.
- ESG lens: In his own words on the Anima deal — *"BNP Paribas Fortis Private Equity is dedicated to investing in Belgian companies that not only drive innovation and growth but also embody our shared values of environmental, social, and governance (ESG) responsibility… we're proud to support their mission-driven approach."*
Notable Investments
- Anima Research (Dec 2024) — Minority investment to fund the European expansion (Netherlands 2025, Germany 2026) of a leading European clinical-trials center known for ~97% patient adherence. Vermeulen was the named BNP Paribas Fortis PE spokesperson on the deal.
- Nobi — Firm investment in the Belgian smart-lighting/fall-detection scale-up for elderly care (BNP Paribas Fortis Private Equity portfolio; firm-level, not confirmed as Vermeulen-led).
- Quality Assistance — Firm portfolio company; BNP Paribas Fortis PE exited on ~Dec 1, 2025 (firm-level).
- Bertin Medical Waste / Posetron / Glunt Industries — Additional recent BNP Paribas Fortis Private Equity portfolio companies across medical-waste treatment, technology, and commercial/industrial services (firm-level).
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.